Transcript ALK-Abell AS, Q2 2023 Earnings Call, Aug 24, 2023 - Marketscreener.com
| DMP Stock | 37.80 0.10 0.26% |
Slightly above 61% of Dermapharm Holding's investor base is looking to short. The analysis of current outlook of investing in Dermapharm Holding SE suggests that many traders are alarmed regarding Dermapharm Holding's prospects. Dermapharm Holding's investing sentiment can be driven by a variety of factors including economic data, Dermapharm Holding's earnings reports, geopolitical events, and overall market trends.
Dermapharm |
Transcript ALK-Abell AS, Q2 2023 Earnings Call, Aug 24, 2023 Marketscreener.com
Read at news.google.com
 |
Dermapharm Holding Fundamental Analysis
We analyze Dermapharm Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermapharm Holding using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermapharm Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Dermapharm Holding is rated below average in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Dermapharm Holding Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermapharm Holding stock to make a market-neutral strategy. Peer analysis of Dermapharm Holding could also be used in its relative valuation, which is a method of valuing Dermapharm Holding by comparing valuation metrics with similar companies.
Peers
Dermapharm Holding Related Equities
| LP6 | LIVZON PHARMAC | 5.59 | ||||
| EVT | Evotec SE | 0.72 | ||||
| MRK | Merck KGaA | 0.18 | ||||
| R2WA | BEXIMCO PHARMAGDR | 0.00 | ||||
| BSFA | ANI Pharmaceuticals | 0.00 | ||||
| DMP | Dermapharm Holding | 0.26 | ||||
| H6D | Haleon PLC | 0.55 | ||||
| S2P | SIMCERE PHARMAC | 1.22 | ||||
| CJH | CanSino Biologics | 3.17 |
Additional Tools for Dermapharm Stock Analysis
When running Dermapharm Holding's price analysis, check to measure Dermapharm Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermapharm Holding is operating at the current time. Most of Dermapharm Holding's value examination focuses on studying past and present price action to predict the probability of Dermapharm Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermapharm Holding's price. Additionally, you may evaluate how the addition of Dermapharm Holding to your portfolios can decrease your overall portfolio volatility.